Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab in untreated locally advanced dMMR/MSI-H rectal cancer in China
NCT06640049Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Oct 2024
- Primary completion
- Oct 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of dostarlimab in rectal cancer, sponsored by GSK. Started Oct 2024; status: active, not recruiting.
02
Drugs
dostarlimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06640049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06640049.